AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH, 2003
(RS. IN LACS)
PARTICULARS
9MONTHS
31.12.2002
3 MONTHS
31.03.2003
3 MONTHS
31.3.2002
YEAR ENDING
31.3.2003
YEAR ENDING
31.03.2002
Audited
Audited
Audited
Audited
Audited
Net Sales/Operational Income
10395.23
4085.42
3206.46
14480.65
11280.92
Others Income
33.91
38.55
2.18
72.46
40.08
TOTAL EXPENDITURE:
9262.41
3635.78
2791.50
12898.19
9911.24
Increase/(decrease) in stock in trade
520.28
-698.77
-134.94
-178.49
73.77
Consumption of Raw Material
8366.35
2356.80
2240.48
10723.15
8638.82
Staff Cost
146.76
54.11
49.14
200.87
192.60
Other expenditure
1269.59
526.10
366.94
1795.69
1153.59
Interest
480.89
194.96
216.10
675.85
617.69
Depreciation
169.77
63.68
47.90
233.45
183.61
Profit(+)/Loss(-) before tax
516.07
229.56
153.14
745.62
608.46
Provision for taxation
34.74
25.36
12.00
60.10
42.00
Provision for deferred tax
61.24
92.19
33.78
153.43
127.40
Net Profit/Loss
420.10
112.00
107.36
532.09
439.06
Provision for dividend on
preference shares
5.57
1.86
0.00
7.43
0.00
Provision for preference dividend tax
0.71
0.24
0.00
0.95
0.00
Retained profit
413.82
109.90
107.36
523.71
439.06
Paid up Equity Share Capital
-
-
-
1304.63
1095.58
Reserve excluding revaluation
reserves of previous accounting year
-
-
-
2551.66
1710.44
EPS (Rs) : (Not Annualised)
- Basic
- Diluted
3.78
3.78
1.00
1.00
1.04
0.99
4.78
4.78
4.23
4.04
Aggregate of non promoters
shareholding
- No. of shares
-% of shareholding
7124289
54.61%
4615800
41.78%
Notes:
a) On annual basis the turnover rose by 28.6%
and the net profit rose by 25%. However during the quarter ended March,03, the profits
rose by over 50% as compared to the figures of the corresponding period in the last
year.
b) The Company completed the expansion of the
capacities of its Macrolide Antibiotics by over 50% during the financial year under
review.
c) To meet the expenditure for setting up of
the new FDA plant and the long term working capital requirements, the Company allotted
13,40,000 equity shares on preferential basis to the bodies corporates at price
of Rs.25/- per share.
d)The previous period figures have been regrouped
and rearranged wherever necessary.
e) The above audited results were taken on record
by the Board of Directors in its meeting held on 28th June, 2003.
For Ind-Swift Laboratories Limited
Sd/-
Sd/-
Place:Chandigarh
(N.R.MUNJAL)
(V.K.MEHTA)
Date:28.06.2003
Managing Director
Jt.Managing Director
To know about our Formulation Division, please visit us at Ind-Swift Limited, our other
group company.
